Table 2.
Clinical characteristics of subjects per disease group analyzed by oligonucleotide array-based gene expression profiling and correlation analysis with clinical parameters
| Condition | N | Sex (men/women) | Age (yr) | GFR (ml/min per 1.73 m2) | Proteinuria (g/d) |
|---|---|---|---|---|---|
| Original cohort | |||||
| LD | 10 | 9:1 | 46±13 | 81±16 | <0.2 |
| DN | 17 | 12:5 | 58±11 | 44±25 | 3.1±2.7 |
| FSGS | 16 | 7:9 | 46±18 | 73±38 | 4.4±2.7 |
| HTN | 20 | 15:5 | 57±12 | 44±25 | 1.4±1.5 |
| IgAN | 24 | 18:6 | 36±15 | 76±38 | 2.4±2.4 |
| MCD | 12 | 8:4 | 36±17 | 101±34 | 6.7±5.8 |
| MGN | 18 | 10:8 | 53±19 | 89±41 | 4.6±3.2 |
| LN | 30 | 7:23 | 35±13 | 64±29 | 3.1±3.3 |
| Thin-membrane disease | 6 | 4:2 | 46±14 | 93±29 | 0.5±0.6 |
| Tumor nephrectomy | 4 | 0:4 | 65±7 | 60±10 | <0.2 |
| Total | 157 | 90:67 | 46±17 | 70±36 | 3.1±3.3 |
| Validation cohort | |||||
| FSGS | 4 | 4:0 | 57±13 | 51±32 | 3.3±3.4 |
| IgAN | 6 | 3:3 | 50±14 | 60±35 | 2.2±2.0 |
| Immuntactoid GN | 1 | 1:0 | 71 | 40 | 0.5 |
| LN | 7 | 1:6 | 34±11 | 76±30 | 4.6±2.4 |
| MCD | 1 | 1:0 | 27 | 152 | 0 |
| MGN | 14 | 6:8 | 46±14 | 92±37 | 5.0±4.0 |
| HTN | 2 | 1:1 | 55±14 | 47±47 | 0.5±0.6 |
| HTN/DN | 1 | 1:0 | 71 | 70 | 15 |
| Vasculitis | 1 | 1:0 | 66 | 22 | 2.1 |
| Amyloidosis | 4 | 2:2 | 53±13 | 49±19 | 2.2±2.0 |
| DN | 2 | 1:1 | 50±14 | 39±13 | 6.0±1.7 |
| Total | 43 | 22:21 | 48±15 | 71±38 | 3.9±3.6 |
GFR and proteinuria are displayed as average values±SD.